60.84Open60.84Pre Close0 Volume0 Open Interest195.00Strike Price0.00Turnover73.82%IV0.76%PremiumDec 20, 2024Expiry Date58.91Intrinsic Value100Multiplier9DDays to Expiry1.93Extrinsic Value100Contract SizeAmericanOptions Type0.9889Delta0.0010Gamma4.29Leverage Ratio-0.0646Theta0.0499Rho4.24Eff Leverage0.0119Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet